Ahmad Alqaqa, MD
Interventional Cardiology · Lakewood, CONPI 1962660423
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,204 of the $14,990 with a category attached, or 61.4%. 39 manufacturers reported payments, led by Medtronic at 33.8% of the total.
Across 318 payments — averaging $47.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Boston Scientific$2K
- Edwards Lifesciences$1K
- CMS Imaging, Inc.$1K
- Amgen$1K
- Abbott$454
- plus $4K from 33 others
What the payments were for
- Travel & lodging$5,34536%
- Food & beverage$9,20461%
- Education$2161%
- Other$2241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 49 | $5,064 |
| Boston Scientific | 60 | $1,603 |
| Edwards Lifesciences | 10 | $1,498 |
| CMS Imaging, Inc. | 3 | $1,283 |
| Amgen | 44 | $1,118 |
| Abbott | 7 | $454 |
| Johnson & Johnson | 18 | $383 |
| Pfizer | 14 | $298 |
| Alnylam Pharmaceuticals Inc. | 10 | $276 |
| Baxter Healthcare | 3 | $267 |
| Cardiovascular Systems Inc. | 3 | $264 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $212 |
| Impulse Dynamics (USA) Inc. | 2 | $195 |
| Astellas Pharma US Inc | 2 | $190 |
| Abiomed | 5 | $189 |
| Sanofi-aventis U.S. LLC | 7 | $162 |
| Inari Medical, Inc. | 1 | $158 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $149 |
| Novartis | 8 | $147 |
| Merck | 7 | $136 |
| Heartflow, Inc. | 8 | $132 |
| E.r. Squibb & Sons, L.L.C. | 6 | $120 |
| AstraZeneca | 6 | $102 |
| Boehringer Ingelheim | 4 | $73 |
| W. L. Gore & Associates, Inc. | 2 | $71 |
| Actelion Pharmaceuticals US, Inc. | 3 | $65 |
| Siemens Medical Solutions USA, Inc. | 1 | $55 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Novo Nordisk | 2 | $49 |
| Angiodynamics, Inc. | 2 | $40 |
| Biotronik Inc. | 1 | $33 |
| Bardy Diagnostics, Inc. | 2 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Bayer | 1 | $19 |
| Aegerion Pharmaceuticals, Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Acell, Inc. | 1 | $13 |
| Ossur Americas, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$1,802
- CoreValve Evolut$1,366
- OPTIMIZER$337
- SYMPLICITY G3$324
- Diamondback Coronary$257
- ELUVIA$167
- RESOLUTE ONYX$164
- Resolute$161
- FLOWTRIEVER CATHETER, S$158
- CT THROMBECTOMY SYSTEM KIT$158
- Impella$149
- SUPERA$141
- Diamondback Peripheral$141
- AZURE XT DR MRI SURESCAN$138
- XIENCE SKYPOINT$138
- Repatha$125
- GENERAL - THERAPIES$121
How this compares
$14,990 in reported general payments places this provider in the 60th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $346,772 |
| Repatha SureclickEvolocumab | 130 | $104,748 |
| EntrestoSacubitril/Valsartan | 37 | $48,609 |
| JardianceEmpagliflozin | 27 | $31,984 |
| XareltoRivaroxaban | 18 | $23,784 |
| FarxigaDapagliflozin Propanediol | 19 | $21,408 |
| Metoprolol Succinate | 400 | $3,771 |
| ClopidogrelClopidogrel Bisulfate | 300 | $3,199 |
| Atorvastatin Calcium | 357 | $2,877 |
| Ezetimibe | 100 | $2,394 |
| Rosuvastatin Calcium | 178 | $2,282 |
| Prasugrel Hcl | 21 | $1,566 |
| Flecainide Acetate | 25 | $1,144 |
| Losartan Potassium | 128 | $931 |
| Torsemide | 28 | $847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $298 | $346,772308 claims |
| NovartisEntresto | $147 | $48,60937 claims |
| Boehringer IngelheimJardiance | $73 | $31,98427 claims |
| Johnson & JohnsonXarelto | $383 | $23,78418 claims |
| AstraZenecaFarxiga | $102 | $21,40819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Lakewood
- Nima AghiliLakewood$220K
- Jeffrey RubinsteinLakewood$22K
- Ashwin MurthyLakewood$17K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.